Algorithmic Evaluation of Metabolic Control and Risk of Severe Hypoglycemia in Type 1 and Type 2 Diabetes Using Self-Monitoring Blood Glucose Data
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The optimization of metabolic control in Type 1 and Type 2 diabetes mellitus (T1DM and T2DM, respectively) [i.e., the maintenance of near-normal hemoglobin A(1c) (HbA(1c)) without increasing the risk of hypoglycemia] could be enhanced by analysis of self-monitoring blood glucose (SMBG) data assessing complementary processes: exposure to hyperglycemia and hypoglycemia. We present algorithms that simultaneously estimate HbA(1)c and risk for significant hypoglycemia using 45-60 days of SMBG. The algorithms were developed using a primary data for 96 subjects with T1DM (n = 48) and T2DM, and were validated in an external data for 520 subjects with T1DM (n = 231) and T2DM. All subjects were on insulin. In the primary (external) data the estimation of HbA(1c) had absolute error of 0.5 (0.7) units of HbA(1c) and percent error of 6.8% (8.1%); 96% (96%) of all estimates were within 20% from reference HbA(1c). The SMBG-estimated value of HbA(1c) was closer to current reference HbA(1c) than a reference HbA(1c) value taken only 2-3 months ago. The results in T1DM and T2DM were similar. Linear model predicted future significant hypoglycemia (R(2) = 62%, p < 0.0001). The leading predictor was a previously introduced Low Blood Glucose Index, which alone had R(2) = 55%. Probability model assessed accurately the odds for future moderate/severe hypoglycemia (coefficients of determination 92%/94%). Four risk categories were identified; within moderate- and high-risk category, there was no difference between T1DM and T2DM in the occurrence of prospective significant hypoglycemia. SMBG data allow for accurate estimation of the two most important markers of metabolic control in T1DM and T2DM - HbA(1c) and risk for hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807 · cited 6×
“15 In short, on one hand, intensive therapy could lead to improved metabolic control and reduced complications in T1DM and T2DM; on the other, intensive therapy was associated with an increase in SH.”
InfluentialEpidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Hypoglycemia in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group (1997) · Diabetes · doi:10.2337/diab.46.2.271 · Cited by 746
Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release.
Amiel, S. A., Sherwin, R. S., Simonson, D. C., & Tamborlane, W. V. (1988) · Diabetes · doi:10.2337/diab.37.7.901 · Cited by 393
White, N. H., Skor, D. A., Cryer, P. E., Levandoski, L. A., Bier, D. M., & Santiago, J. V. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303033080903 · Cited by 391 · cited 1×
“…various measures to assess the risk of SH have been tested, including low HbA 1c , 6,19 intensive therapy and inadequate counterregula-tion, 26–30 and hypoglycemia unawareness and history of SH. 4,6,19 Such measures accounted for up to 18% of future SH episodes in a structural equations model…”
Avignon, A., Radauceanu, A., & Monnier, L. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1822 · Cited by 363
Amiel, S. A., Tamborlane, W. V., Simonson, D. C., & Sherwin, R. S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162205 · Cited by 309
Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus
Epstein, F. H., Cryer, P. E., & Gerich, J. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198507253130405 · Cited by 273
Plasma Glucose Levels Throughout the Day and HbA1c Interrelationships in Type 2 Diabetes
Bonora, E., Calcaterra, F., Lombardi, S., Bonfante, N., Formentini, G., Bonadonna, R. C., & Muggeo, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2023 · Cited by 235 · cited 1×
“This uncertainty is confirmed by reports claiming that HbA 1c was more related to preprandial than postprandial plasma/blood glucose levels, 22 or the opposite, 23 or that the influence of the timing of BG determination is unclear.”
Reichard, P., & Pihl, M. (1994) · Diabetes · doi:10.2337/diab.43.2.313 · Cited by 147
Cited by
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Diabetes: Models, Signals, and Control
Cobelli, C., Dalla Man, C., Sparacino, G., Magni, L., De Nicolao, G., & Kovatchev, B. P. (2009) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2009.2036073 · Cited by 511
“The LBGI, which is based on the left branch of the BG Risk Function r(BG) has been validated as an excellent predictor of future significant hypoglycemia [186], [187].”
Self-citationHill, N. R., Oliver, N. S., Choudhary, P., Levy, J. C., Hindmarsh, P., & Matthews, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0247 · Cited by 362
A Novel Approach to Continuous Glucose Analysis Utilizing Glycemic Variation
McDonnell, C. M., Donath, S. M., Vidmar, S. I., Werther, G. A., & Cameron, F. J. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.253 · Cited by 358
Metadata
- Authors
- Kovatchev, B. P., Cox, D. J., Kumar, A., Gonder-Frederick, L., & Clarke, W. L.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2003-10
- Volume
- 5
- Issue
- 5
- Pages
- 817-828
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2177333643
- Cited by
- 146
- References
- 12
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Algorithmic Evaluation of Metabolic Control and Risk of Severe Hypoglycemia in Type 1 and Type 2 Diabetes Using Self-Monitoring Blood Glucose Data. https://app.cochat.ai/papers/10.1089/152091503322527021
- The paper
- Kovatchev, B. P., Cox, D. J., Kumar, A., Gonder-Frederick, L., & Clarke, W. L. (2003). Algorithmic Evaluation of Metabolic Control and Risk of Severe Hypoglycemia in Type 1 and Type 2 Diabetes Using Self-Monitoring Blood Glucose Data. Diabetes Technology & Therapeutics. https://doi.org/10.1089/152091503322527021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.